Siliq_Medical_Necessity_Criteria
Defines Cigna prior authorization and medical necessity criteria for Siliq (brodalumab subcutaneous injection) for plaque psoriasis in adults, including initial and continuation approval criteria, exclusions, safety/REMS requirements, and appendix of related biologics and oral therapies.
Exception to trial of a traditional systemic agent: a 3-month trial or prior intolerance to Otezla/Otezla XR or Sotyktu was added.
For initial approval and continuation, requirements were changed to 'According to the prescriber' for evaluation and absence of depression/behaviors.
For patients currently on Siliq, timeframe for 'established on therapy' standardized to 3 months.
Conditions Not Covered text updated to specify 'Concurrent use with a Biologic or with a Targeted Synthetic Oral Small Molecule Drug.'
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.